These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17610400)

  • 1. The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model.
    de la Puente-Redondo V; Tingley FD; Schneider RP; Hickman MA
    J Vet Pharmacol Ther; 2007 Aug; 30(4):281-7. PubMed ID: 17610400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
    Benchaoui HA; Cox SR; Schneider RP; Boucher JF; Clemence RG
    J Vet Pharmacol Ther; 2007 Aug; 30(4):336-44. PubMed ID: 17610407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs.
    Boscan P; Monnet E; Mama K; Twedt DC; Congdon J; Steffey EP
    Am J Vet Res; 2011 Dec; 72(12):1576-9. PubMed ID: 22126683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
    Ramsey DS; Kincaid K; Watkins JA; Boucher JF; Conder GA; Eagleson JS; Clemence RG
    J Vet Pharmacol Ther; 2008 Dec; 31(6):538-43. PubMed ID: 19000277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs.
    de la Puente-Redondo VA; Tilt N; Rowan TG; Clemence RG
    Am J Vet Res; 2007 Jan; 68(1):48-56. PubMed ID: 17199418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
    Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
    Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats.
    Hickman MA; Cox SR; Mahabir S; Miskell C; Lin J; Bunger A; McCall RB
    J Vet Pharmacol Ther; 2008 Jun; 31(3):220-9. PubMed ID: 18471143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.
    Conder GA; Sedlacek HS; Boucher JF; Clemence RG
    J Vet Pharmacol Ther; 2008 Dec; 31(6):528-32. PubMed ID: 19000275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days.
    Lesman SP; Boucher JF; Grover GS; Cox SR; Bidgood TL
    J Vet Pharmacol Ther; 2013 Oct; 36(5):462-70. PubMed ID: 23167698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat.
    Field MJ; McCleary S; Boden P; Suman-Chauhan N; Hughes J; Singh L
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1226-32. PubMed ID: 9618426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
    Shishido Y; Wakabayashi H; Koike H; Ueno N; Nukui S; Yamagishi T; Murata Y; Naganeo F; Mizutani M; Shimada K; Fujiwara Y; Sakakibara A; Suga O; Kusano R; Ueda S; Kanai Y; Tsuchiya M; Satake K
    Bioorg Med Chem; 2008 Aug; 16(15):7193-205. PubMed ID: 18640044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of refrigeration of the antiemetic Cerenia (maropitant) on pain on injection.
    Narishetty ST; Galvan B; Coscarelli E; Aleo M; Fleck T; Humphrey W; McCall RB
    Vet Ther; 2009; 10(3):93-102. PubMed ID: 20037963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs.
    Sedlacek HS; Ramsey DS; Boucher JF; Eagleson JS; Conder GA; Clemence RG
    J Vet Pharmacol Ther; 2008 Dec; 31(6):533-7. PubMed ID: 19000276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of maropitant citrate after oral administration of multiple doses in adult horses.
    Berryhill EH; Knych H; Chigerwe M; Edman J; Magdesian KG
    J Vet Pharmacol Ther; 2020 May; 43(3):282-287. PubMed ID: 32067245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the effect of bilateral amygdala lesions on fear conditioning and social interaction in the male Mongolian gerbil.
    Woolley ML; Haman M; Higgins GA; Ballard TM
    Brain Res; 2006 Mar; 1078(1):151-8. PubMed ID: 16494851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret.
    Singh L; Field MJ; Hughes J; Kuo BS; Suman-Chauhan N; Tuladhar BR; Wright DS; Naylor RJ
    Eur J Pharmacol; 1997 Feb; 321(2):209-16. PubMed ID: 9063690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
    Brocco M; Dekeyne A; Mannoury la Cour C; Touzard M; Girardon S; Veiga S; de Nanteuil G; deJong TR; Olivier B; Millan MJ
    Eur Neuropsychopharmacol; 2008 Oct; 18(10):729-50. PubMed ID: 18657401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist.
    Ballard TM; Sänger S; Higgins GA
    Eur J Pharmacol; 2001 Feb; 412(3):255-64. PubMed ID: 11166289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.